Conference abstractPublished 27 Nov 2021
Introducing of two probiotics as anti-flatulence agents
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Flatulence is a symptom of indigestion and is usually caused by eating certain foods that cause bloating. Humans are not able to digest oligosaccharides with alpha-galactosyl moieties, therefore, the consumption of legumes which naturally have high concentrations of indigestible oligosaccharides, ultimately fermented by the colonic flora and cause to produce gas. The enzyme alpha-galactosidase could break down the terminal alpha-galactosyl moieties from glycolipids, glycoproteins, and oligosaccharides to give low molecular weight products. Thus, using capable alpha-galactosidase-producing probiotics could be suggested to be a safe approach for the reduction of gastrointestinal gas besides other benefits. The aim of this study is the screening of alpha galactosidase-producing probiotics with anti-flatulence potential. Methodology & Theoretical Orientation: Bacterial strains were selected from the Bacterial Culture Collection of Shiraz University of Medical Sciences (BCCS) and screened on MRS plates containing 0.01% bromocresol purple to select alpha-galactosidase-producing bacteria. Alpha galactosidase activity was assayed. For probiotic characterization, all probiotic evaluated tests were done. Findings: Among 121 bacteria, 21 strains produced alpha-galactosidase and were defined as probiotics. Lactobacillus acidophilus strain BCCS A49 with 0.6±0.05 U/mL activity and Lactobacillus acidophilus strain BCCS A50 with 0.86±0.04 U/mL activity produced a high yield of alpha-galactosidase. Conclusion & Significance: These strains could be selected to use as therapeutic agents to reduce gastrointestinal gas by replacement with colonic flora, in a safe approach with further studies.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Biotechnology: Current Research
- SubjectPharmaceutical Sciences
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Aboozar Kazemi”
